Status:
COMPLETED
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease
Lead Sponsor:
MedImmune LLC
Conditions:
Stable Coronary Heart Disease
Eligibility:
All Genders
45-80 years
Phase:
PHASE2
Brief Summary
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Adults With Stable Coronary Heart Disease.
Detailed Description
A Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Participants with Stable Coronary Heart Dis...
Eligibility Criteria
Inclusion
- Diagnosis of stable coronary heart disease prior to screening
- Currently receiving high intensity statin(s)
Exclusion
- Unstable cardiovascular conditions
- Any planned arterial revascularizations
- Fasting Laboratory values at screening: Triglycerides \> 500 mg/dl, Low Density Lipoprotein-Cholesterol \> 100 mg/dL
- Any disease or condition or laboratory value that would place the participant at an unacceptable risk.
Key Trial Info
Start Date :
December 13 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2018
Estimated Enrollment :
133 Patients enrolled
Trial Details
Trial ID
NCT03351738
Start Date
December 13 2017
End Date
November 9 2018
Last Update
March 23 2020
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Anniston, Alabama, United States, 36207
2
Research Site
Huntsville, Alabama, United States, 35801
3
Research Site
El Cajon, California, United States, 92020
4
Research Site
Lincoln, California, United States, 95648